Akari Therapeutics (AKTX) Shares Outstanding (Weighted Average) (2011 - 2026)

Akari Therapeutics' Shares Outstanding (Weighted Average) history runs 16 years deep, the most recent figure standing at $118.8 billion for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 117.55% year-over-year to $118.8 billion; the TTM figure through Mar 2026 stood at $118.8 billion (up 117.55% YoY), while the FY2025 annual figure was $1.7 million, down 99.99% from the prior year.
• Shares Outstanding (Weighted Average) came in at $118.8 billion for Q1 2026 at Akari Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $118.8 billion in Q1 2026 to a low of $1.7 million in Q4 2025.
• A 5-year average of $26.4 billion and a median of $11.8 billion in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• Across the five-year window, Shares Outstanding (Weighted Average) surged 1211.65% in 2022 and tumbled 99.99% in 2025, its largest moves.
• Akari Therapeutics' Shares Outstanding (Weighted Average) stood at $6.2 billion in 2022, then soared by 56.79% to $9.8 billion in 2023, then soared by 144.03% to $23.9 billion in 2024, then sank by 99.99% to $1.7 million in 2025, then surged by 7082099.56% to $118.8 billion in 2026.
• According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $118.8 billion, $1.7 million, and $61.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison